## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor:

Han Ting Chang, et al.

Group Art Unit:

Serial Number:

10/806,495

Examiner:

Robert D. Harlan

Filing Date:

March 22, 2004

**CONFIRMATION NO: 2769** 

Title: CROSSLINKED AMINE POLYMERS

FILED ELECTRONICALLY ON: OCTOBER 23, 2006

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR §1.97**

Sir:

Applicant(s) hereby submit(s) an Information Disclosure Statement along with attached form(s) PTO/SB/08. A copy of each listed publication is submitted, if required, pursuant to 37 CFR §§1.97-1.98, as indicated below.

Applicant(s) respectfully request(s) that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicant(s) further request(s) that the Examiner initial and return the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

-1-

A.	because:	K §1.97	(b). This Information Disclosure Statement should be considered by the Office
		(1)	It is being filed within 3 months of the filing date of a national application and is other than a continued prosecution application under §1.53(d);
			OR
		(2)	It is being filed within 3 months of entry of the national stage as set forth in §1.491 in an international application;
			OR
	$\boxtimes$	(3)	It is being filed before the mailing of a first Office action on the merits;
			OR
		(4)	It is being filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
В.	specified in office action	n <i>37 CF</i> on under secution	(c). Although this Information Disclosure Statement is being filed after the period $(R, \S1.97(b))$ , above, it is filed before the mailing date of the earlier of (1) a final $(\S1.113, \S1.113, \S1.11$
		a stater	ment as specified in §1.97(e) provided concurrently herewith;
			OR
			f \$180.00 as set forth in §1.17(p) authorized below, enclosed, or included with the nt of other papers filed together with this statement.
C.	date of the	earlier o	d). Although this Information Disclosure Statement is being filed after the mailing of (1) a final office action under §1.113 or (2) a notice of allowance under §1.311, fore payment of the issue fee and should be considered because it is accompanied
		i. a st	atement as specified in §1.97(e);
			AND
			ee of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included he the payment of other papers filed together with this Statement.
D.	37 CFI	R §1.97(	e). Statement.
		A state	ement is provided herewith to satisfy the requirement under 37 CFR §§1.97(c);
			AND/OR
		A state	ement is provided herewith to satisfy the requirement under 37 CFR §§1.97(d);
			AND/OR
		inform	y of a dated communication from a foreign patent office clearly showing that the ation disclosure statement is being submitted within 3 months of the filing date on mmunication is provided in lieu of a statement under 37 C.F.R. § 1.97(e)(1) as ed for under MPEP 609.04(b) V.
Е.	disclosure application	statemer that wa	der 37 C.F.R. §1.704(d). Each item of information contained in the information in the was first cited in a communication from a foreign patent office in a counterpart is received by an individual designated in § 1.56(c) not more than thirty (30) days of this information disclosure statement. This statement is made pursuant to the

		ats of 37 C.F.R. §1.704(d) to avoid reduction of the period of adjustment of the patent term ant(s) delay.
F.	⊠ 37 CFI	$R \S 1.98(a)(2)$ . The content of the Information Disclosure Statement is as follows:
		Copies of each of the references listed on the attached Form PTO/SB/08 are enclosed herewith.
		OR
	$\boxtimes$	Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08 are NOT enclosed.
		AND/OR
	$\boxtimes$	Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08 are enclosed in accordance with 37 CFR §1.98 (a)(2).
		AND/OR
		Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98(a)(2)(iii).
G.	⊠ 37 CF references.	R §1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or
		Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.
		Pursuant to MPEP 609(B), an English language copy of a foreign search report is submitted herewith to satisfy the requirement for a concise explanation where non-English language information is cited in the search report.
		OR
		A concise explanation of the relevance of each patent, publication or other information provided that is not in English is as follows:
	$\boxtimes$	Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation, or a portion thereof, of the non-English language reference(s) is provided herewith.
H.	☐ 37 CF	$R \le 1.98(d)$ . Copies of patents, publications and pending U.S. patent applications, or other a specified in 37 C.F.R. § 1.98(a) are not provided herewith because:
		Pursuant to 37 CFR §1.98(d)(1) the information was previously submitted in an Information Disclosure Statement for another application under which this application claims priority for an earlier effective filing date under 35 U.S.C. 120.
		Application in which the information was submitted:
		Information Disclosure Statement(s) filed on:
	_	AND
		The information disclosure statement submitted in the earlier application complied with paragraphs (a) through (c) of 37 CFR §1.98.

I. Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No. 29329-749.201).

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Dated: October 23, 2006

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 056631

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE				Complete if Known		
				Application Number	10/806,495	
				Filing Date	March 22, 2004	
STATEMENT BY APPLICANT			LICANT	First Named Inventor	Han Ting Chang	
(Use as	(Use as many sheets as necessary)			Art Unit	1713	
				Examiner Name	Robert D. Harlan	
Sheet	1	Of	2	Attorney Docket Number	29329-749.201	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. 1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear			
	70.	US 2005/0276781 A1	12-15-2005	Ross et al.				
	71.	US 6,180,754 B1	01-30-2001	Stutts et al.				
	72.	US 6,333,051 B1	12-25-2001	Kabanov et al.				
	73.	US 6,362,266 B1	03-26-2002	Buchholz et al.				

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>1</sup> – Number <sup>4</sup> – Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ <sup>6</sup>		
	74.	WO 01/38423 A1	05-31-2001	Neste Chemicals OY				
	75.	WO 02/32974 A2	04-25-2002	Fujisawa Pharmaceutical Co., Ltd.				
	76.	WO 02/032974 A3	04-25-2002	Fujisawa Pharmaceutical Co., Ltd.				
	77.	WO 2006/040579 A1	04-20-2006	The University Court of the University of Glasgow				

Examiner	Date	
Signature	Consi	lamad
Signature	Const	iered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute for	or form 1449	9/PTO		Application Number	10/806,495	
INFORM	IATION	DISC	LOSURE	Filing Date	March 22, 2004	
1			LICANT	First Named Inventor	Han Ting Chang	
(Use as	many sheet	ts as nec	cessary)	Art Unit	1713	
				Examiner Name	Robert D. Harlan	
Sheet	2	Of	2	Attorney Docket Number	29329-749.201	

	NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>						
	78.	DANIEL, Marie-Christine, et al. 2003. Supramolecular H-Bonded Assemblies of Redox-Active Metallodendrimers and Positive and Unusual Dendritic Effects on the Recognition of H2PO4. J. Am. Chem Soc. 125(5): 1150-1151.							
	79.	KIOUSSIS, Dimitri R., et al. 2005. Characterization of anion diffusion in polymer hydrogels used for wastewater remediation. <i>Polymer</i> . 46: 9342-9347.							
	80.	KIOUSSIS, Dimitri R., et al. 2005. Characterization of network morphology in anion binding hydrogels used for wastewater remediation. <i>Polymer.</i> 46: 10167-10172.							
	81.	MAZZEO, Jeffrey R., et al. 1999. A phosphate binding assay for sevelamer hydrochloride by ion chromatography. J. Pharm. Biomed. Anal. 19: 911-915.							
	82.	PANOVA, T.V., et al. 2004. Interaction of Poly(propylenimine) Dendrimers with Polyanionic Hydrogels. Faculty of Chemistry, Moscow State University. 46(5): 783-798. (in Russian with English Abstract)							
	83.	TIITU, Mari, et al. 2005. Aminic epoxy resin hardeners as reactive solvents for conjugated polymers; polyaniline base/epoxy composites for anticorrosion coatings. <i>Polymer</i> . 46: 6855-6861.							

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw time through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Simil of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

circle transfer that never in English language Pransfation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, cull 1-800-PTO-9199 (1-800-786-9199) and select option 2.